*Some Market data delayed by 15 mins.

NewAmsterdam Pharma Company N.V. Ordinary Shares

Symbol: NAMS (NASDAQ)
0.00 ▼ (-100.00%) -26.600

Company Description:
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Key Stats
  • Today's Open: $0
  • Today's High: $0
  • Today's Low: $0
  • Today's Volume: 0
  • Yesterday Close: $26.6
  • Yesterday High: $27.35
  • Yesterday Low: $25.5545
  • Yesterday Volume: 2.25M
  • Last Min Volume: 0
  • Last Min High: $0
  • Last Min Low: $0
  • Last Min VWAP: $0
Company Profile
  • Name: NewAmsterdam Pharma Company N.V. Ordinary Shares
  • Website: https://www.newamsterdampharma.com
  • Listed Date: 2022-11-23
  • Location: NARRDEN, P7
  • Market Status: Active
  • CIK Number: 0001936258
  • SIC Code: 2834
  • SIC description: PHARMACEUTICAL PREPARATIONS
  • Market Cap: $3.03B
  • Round Lot: 100
  • Outstanding Shares: 112.63M
  • Asset Type: CS
RECENT FILINGS FOR NAMS
Filing Date Filing Type Format
2025-09-10 4 View
2025-09-10 4 View
2025-09-09 144 View
2025-09-05 4 View
2025-09-04 4 View
2025-09-03 144 View
2025-09-02 8-K View
2025-08-27 4 View
2025-08-27 144 View
2025-08-25 4 View
2025-08-25 144 View
2025-08-20 SCHEDULE 13D/A View
2025-08-18 8-K View
2025-08-15 8-K View
2025-08-13 4 View
2025-08-13 SCHEDULE 13G/A View
2025-08-12 SCHEDULE 13D/A View
2025-08-06 8-K View
2025-08-06 10-Q View
2025-07-30 8-K View

 

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money. Copyright© 2024, 247MarketNews inc.